Perspectives on Genetically Engineered Microorganisms and Their Regulation in the United States
Shams A, Fischer A, Bodnar A, and Kliegman M. ACS Synthetic Biology
(2024)We work diligently to:
Our science policy and regulatory focus spans all research areas of the IGI, from health to agriculture to emerging technologies.
At the IGI, we aim to empower regulators from low- and middle-income countries (LMICs) with technical knowledge on CRISPR genome editing.
We inform regulators about advances in cutting edge CRISPR technologies to help them prepare for emerging regulatory considerations.
Learn more here and find the recordings from the workshop and summary findings here.
The IGI partnered with the American Society of Hematology (ASH) Research Collaborative and the U.S. Food and Drug Administration (FDA) to discuss real-world evidence for genomic therapies. Learn more >
Download the Genomic Therapies Work Group’s final report here
Download the Coordinated Registry Network Work Group’s here
We engage our network of experts to respond to government requests for information (RFIs), proposed rules, and draft regulatory documents that impact gene therapy development and genome editing technologies in the agricultural sector.
Government Request for Input |
IGI Response (click to download PDF) |
FDA Draft Guidance on Manufacturing Changes and Comparability Assessment of Cellular and Gene Therapy Products (FDA-2023-D-2436) |
|
FDA RFI on Individualized Cellular and Gene Therapy Product Development (FDA-2023-N-3742) |
|
ARPA-H RFI on Ethical, Legal, and Social Implication (ELSI) Framework |
|
OSTP Request for Information on the Coordinated Framework (APHIS-2022-0076) |
|
OSTP RFI on Biotechnology and Biomanufacturing Initiative (FR Doc. 2022-27600) |
|
FDA Draft Guidance on Gene Therapy Products Incorporating Genome Editing (FDA-2021-D-0398) |
|
NCATS RFI on Early Detection and Equitable Gene Therapy Delivery for Rare Diseases (NOT-TR-21-027) |
|
USDA Proposed Rule on Movement of Certain Genetically Engineered Organisms (APHIS-2018-0034) |
|
FDA Draft Guidance on Chemistry, Manufacturing, and Controls of Gene Therapy INDs (FDA-2008-D-0205) |
|
FDA Draft Guidance on Long-Term Follow-Up for Gene Therapy Products (FDA-2018-D-2173) |
Shams A, Fischer A, Bodnar A, and Kliegman M. ACS Synthetic Biology
(2024)Ecker DJ, Aiello CD, Arron JR, Bennett CF, Bernard A, Breakefield XO, Broderick TJ, Callier SL, Canton B, Chen JS, Fishburn CS, Garrett B, Hecht SM, Janowitz T, Kliegman M, Krainer A, Louis CU, Lowe C, Sehgal A, Tozan Y, Tracey KJ, Urnov F, Wattendorf D, Williams TW, Zhao X, and Hayden MR. Nature Reviews Drug Discovery
(2024)Witkowsky L, Norstad M, Glynn AR, and Kliegman M. Gene Therapy
(2023)Taitingfong RI, Triplett C, Vásquez VN ... Marshall JM, Montague M, Morrison AC, Opesen CC, Phelan R, Piaggio A, Quemada H, Rudenko L, Sawadogo N, Smith R, Tuten H, Ullah A, Vorsino A, Windbichler N, Akbari OS, Long K, Lavery JV, Evans SW, Tountas K, Bloss CS. Nature Biotechnology
(2022)Please feel free to reach out to the IGI Public Impact team with any inquiries about genome editing policy and regulations.
Health and innovation policy: Manar Zaghlula, manar.zaghlula@berkeley.edu
Agriculture and climate policy: Elizabeth Njuguna, ewnjuguna@berkeley.edu